Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses

Vaccine

Volumn 26, Issue 5, 2008, Pages 614-622

  Zhang, Yongxin ^a   Qiu, Jianxia ^a   Zhou, Yu ^a   Farhangfar, Farhang ^a   Hester, Jenny ^a   Lin, Augustine Y ^a   Decker, William K ^b  

^a MithraGen Inc   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anthrax; Dendritic cell; DNA vaccination; Th 1 response; Vaccine

Indexed keywords

ANTHRAX VACCINE; EXOTOXIN; GAMMA INTERFERON; MEMBRANE PROTEIN; PLASMID DNA; PROTEIN EA1; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; BACTEREMIA; CONTROLLED STUDY; CYTOLYSIS; DRUG FORMULATION; EPIGENETICS; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; MACROPHAGE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SPLEEN CELL; SPORE GERMINATION; TH1 CELL; TH2 CELL; VACCINATION;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL PROTEINS; BACTERIAL TOXINS; EPIGENESIS, GENETIC; EXOTOXINS; FEMALE; INTERFERON TYPE II; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PLASMIDS; PROTEIN SUBUNITS; SPECIES SPECIFICITY; TH1 CELLS; TH2 CELLS; VACCINATION; VACCINES, SYNTHETIC;

EID: 37849038903     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.072     Document Type: Article

References (41)

1. Shafazand S., Doyle R., Ruoss S., Weinacker A., and Raffin T.A. Inhalation anthrax: epidemiology, diagnosis, and management. Chest 116 5 (1999) 1369-1376
2. Dixon T.C., Meselson M., Guillemin J., and Hanna P.C. Anthrax. N Engl J Med 341 11 (1999) 815-826
3. Little S.F., and Ivins B.E. Molecular pathogenesis of Bacillus anthracis infection. Microbes Infect 1 2 (1999) 131-139
4. Nass M. Anthrax vaccine: model of a response to the biologic warfare threat. Infect Dis Clin North Am 13 1 (1999) 187-208
5. Demicheli V., Rivetti D., Deeks J.J., Jefferson T., and Pratt M. The effectiveness and safety of vaccines against human anthrax: a systematic review. Vaccine 16 9-10 (1998) 880-884
6. Modlin J.F., Snider D.E., Brooks D.A., Clover D.R., Guerra F.A., Helms C.M., et al. Use of anthrax vaccine in the United States: recommendations of the advisory committee on immunization practices. J Toxicol Clin Toxicol 39 1 (2001) 85-100
7. Meselson M., Guillemin J., Hugh-Jones M., Langmuir A., Popova I., Shelokov A., et al. The Sverdlovsk anthrax outbreak of 1979. Science 266 5188 (1994) 1202-1208
8. Kaufmann A.F., Meltzer M.I., and Schmid G.P. The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justified?. Emerg Infect Dis 3 2 (1997) 83-94
9. Williamson E.D., Beedham R.J., Bennett A.M., Perkins S.D., Miller J., and Baillie L.W. Presentation of protective antigen to the mouse immune system: immune sequelae. J Appl Microbiol 87 2 (1999) 315-317
10. Phipps A.J., Premanandan C., Barnewall R.E., and Lairmore M.D. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol Mol Biol Rev 68 4 (2004) 617-629
11. Little S.F., Ivins B.E., Webster W.M., Fellows P.F., Pitt M.L., Norris S.L., et al. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24 14 (2006) 2530-2536
12. Fowler G.L., Baggs J.M., Weintraub E.S., Martin S.W., McNeil M.M., and Gust D.A. Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program. Pharmacoepidemiol Drug Saf 15 12 (2006) 880-888
13. Stepanov A.V., Marinin L.I., Pomerantsev A.P., and Saritsin N.A. Development of novel vaccines against anthrax in man. J Biotechnol 44 1-3 (1996) 155-160
14. Cohen S., Mendelson I., Altboum Z., Kobiler D., Elhanany E., Bino T., et al. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun 68 8 (2000) 4549-4558
15. Fouet A., Mesnage S., Tosi-Couture E., Gounon P., and Mock M. Bacillus anthracis surface: capsule and S-layer. J Appl Microbiol 87 2 (1999) 251-255
16. Mesnage S., Tosi-Couture E., Mock M., Gounon P., and Fouet A. Molecular characterization of the Bacillus anthracis main S-layer component: evidence that it is the major cell associated antigen. Mol Microbiol 23 6 (1997) 1147-1155
17. Ezzell J.W., and Welkos S.L. The capsule of Bacillus anthracis, a review. J Appl Microbiol 87 2 (1999) 250
18. Glomski I.J., Corre J.P., Mock M., and Goossens P.L. Cutting edge: IFN-gamma-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis. J Immunol 178 5 (2007) 2646-2650
19. Price B.M., Liner A.L., Park S., Leppla S.H., Mateczun A., and Galloway D.R. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 69 7 (2001) 4509-4515
20. Goletz T.J., Klimpel K.R., Leppla S.H., Keith J.M., and Berzofsky J.A. Delivery of antigens to the MHC class I pathway by using bacterial toxins. Hum Immunol 54 2 (1997) 129-136
21. Leppla S.H., Arora N., and Varughese M. Anthrax toxin fusion proteins for intracellular delivery of macromolecules. J Appl Microbiol 87 2 (1999) 284
22. Sirard J.C., Fayolle C., De Chastellier C., Mock M., Leclerc C., and Berche P. Intracytoplasmic delivery of listeriolysin O by a vaccinal strain of Bacillus anthracis induces CD8-mediated protection against listeria monocytogenes. J Immunol 159 9 (1997) 4435-4443
23. Decker W.K., Qiu J., Farhangfar F., Hester J.H., Altieri D.C., and Lin A.Y. A retrogen plasmid-based vaccine generates high titer antibody responses against the autologous cancer antigen surviving and demonstrates anti-tumor efficacy. Cancer Lett 237 1 (2006) 45-55
24. Hauser H., Shen L., Gu Q.L., Krueger S., and Chen S.Y. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther 11 11 (2004) 924-932
25. Hauser H., and Chen S.Y. Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. Methods 31 3 (2003) 225-231
26. You Z., Huang X., Hester J., Toh H.C., and Chen S.Y. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res 61 9 (2001) 3704-3711
27. You Z., Hester J., Rollins L., Spagnoli G.C., Van der Bruggen P., and Chen S.Y. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. Cancer Res 61 1 (2001) 197-205
28. You Z., Huang X.F., Hester J., Rollins J., Rooney C., and Chen S.Y. Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway. J Immunol 165 8 (2000) 4581-4591
29. 1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 93 10 (1996) 5141-5145
30. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 10 (2004) 987-995
31. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203 2 (2006) 413-424
32. Duenas A.I., Aceves M., Orduna A., Diaz R., Sanchez Crespo M., and Garcia-Rodriguez C. Francisella tularensis LPS induces the production of cytokines in human monocytes and signals via Toll-like receptor 4 with much lower potency than E. coli LPS. Int Immunol 18 5 (2006) 785-795
33. Bieback K., Lien E., Klagge I.M., Avota E., Schneider-Schaulies J., Duprex W.P., et al. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol 76 17 (2002) 8729-8736
34. Hahn U.K., Aichler M., Boehm R., and Beyer W. Comparison of the immunological memory after DNA vaccination against anthrax in sheep. Vaccine 24 21 (2006) 4595-4597
35. Hahn U.K., Boehm R., and Beyer W. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine 24 21 (2006) 4569-4571
36. Hahn U.K., Alex M., Czerny C.P., Böhm R., and Beyer W. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination. Int J Med Microbiol 294 1 (2004) 35-44
37. Hermanson G., Whitlow V., Parker S., Tonsky K., Rusalov D., Ferrari M., et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 101 37 (2004) 13601-13606
38. Galloway D., Liner A., Legutki J., Mateczun A., Barnewall R., and Estep J. Genetic immunization against anthrax. Vaccine 22 13-14 (2004) 1604-1608
39. Gu M.L., Leppla S.H., and Klinman D.M. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 17 4 (1999) 340-344
40. Shedlock D.J., and Shen H. Requirement for CD4 T-cell help in generating functional CD8 T-cell memory. Science 300 5617 (2003) 337-339
41. + T-lymphocytes. Nature 421 6925 (2003) 852-856